Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

7:15 am 8 am (45 mins)

Main agenda

Workshop Registration

8 am 8:30 am (30 mins)

Workshop 1

Workshop Introduction

  • Workshop Leader Marc Jacob, Ph.D. - Product Manager, Chiral and Preparative Chromatography, Phenomenex
  • Workshop Leader Trishul Shah - Associate Director, Business Development, North America, PolyPeptide Laboratories

8:30 am 9:15 am (45 mins)

Workshop 1

A Holistic Quality Control Strategy for Peptide APIs

The quality of peptide APIs is influenced by multiple critical parameters during analytical and process development, and routine manufacturing. In this context the application of state-of-the-art analytical technologies is crucial. The presentation will highlight the most critical success factors from an analytical point of view. This includes a thorough development of analytical procedures, a sound analytical support of the process development, as well as a specific and efficient in-process control strategy for each manufacturing stage. Special focus is laid upon the assurance of the quality of starting materials, a further key element of a holistic quality control strategy for peptide APIs.

  • Presenter Tobias Hauck, Ph.D. - Vice President, Quality Control, Bachem AG

9:15 am 9:45 am (30 mins)

Workshop 1

NMR Spectroscopy Applied to Peptides and Peptide Impurities – Case Studies

The aim of this talk is to highlight the potential value of an increased use of NMR spectroscopy for studies of peptides and peptide impurities. A couple of case studies will be presented including structural characterisation of peptides, quantitative and structural analysis of small molecule and peptide impurities in peptide samples as well as the effectiveness of NMR for comparison of different peptides batches.

  • Presenter Johan Evenäs, Ph.D. - Chief Executive Officer, Read Glead Discovery

9:45 am 10 am (15 mins)

Workshop 1

Refreshment Break

10 am 10:30 am (30 mins)

Workshop 1

General Overview of Peptide Analysis by Mass Spectrometry

The lecture presents the mass spectrometry as a very powerful “tool” of modern analytical chemistry in hands of chemists / scientists performing research or just routine quality control testing of peptides and/or peptoids. The proper use of terminology, interpretation of MS data, main components of mass spectrometers, general LC-MS methodology, with the main emphasis on the most important ionization techniques optimal for MS analysis of these compounds is presented.

  • Presenter Jiri Snopek, Ph.D. - Mass Spectrometry Lab Manager, PolyPeptide Laboratories

10:30 am 11 am (30 mins)

Workshop 1

MS Peak Homogeneity: The Use of Mass Spectrometry as a Tool for LC Method Specificity

The concept of UV Spectral Purity is a well-established technique utilized by the pharmaceutical industry to confirm specificity of HPLC analytical methods for small molecules. It relies on the differences in UV absorbance spectrum between API and impurities. This approach cannot be applied to the peptide industry due to the comparable UV spectrums between the API and the peptidic impurities. The focus of the talk will be on the use of mass spectral techniques to assure that the analytical HPLC methods developed to define API purity presents an appropriate specificity as defined by ICH Q2 (R1). The discussion will focus on the use of mass spectroscopy to determine purity method specificity. The presentation will define instances where MS can support method specificity. Conversely, it will present solutions for impurities that are not correctly defined by MS. The approach to peak purity adopted by Bachem Americas during method development and method pre-validation will be described in detail.

  • Presenter Sumukh Ray - Manager, Method Development, Bachem Americas

11 am 12 pm (60 mins)

Workshop 1

Panel Discussion

8 am 8:20 am (20 mins)

Workshop 2

Introductory Remarks

The definition of an oligonucleotide therapeutic has greatly expanded in the past few years with the introduction of novel technologies such as messenger RNAs and CRISPR/CAS9 systems. Furthermore, even the more established oligonucleotide modalities (antisense, siRNA, aptamers, microRNA, etc.) have seen a dramatic increase in the complexity of drug candidates being promoted into preclinical and clinical development. These oligonucleotides often have significant chemical modifications requiring specialty starting materials as well as technical innovations in process development, analytical chemistry, manufacturing and controls. This places extraordinary demands on both sponsor companies and contract service organizations to meet regulatory expectations while ensuring patient safety, often under aggressive timelines. This workshop will present case studies of CMC development of emerging technologies from the perspective of sponsors, CMO and Quality Assurance.

  • Workshop Leader G. Susan Srivatsa, Ph.D. - President, ElixinPharma
  • Workshop Leader Fran Wincott, Ph.D. - President, Wincott & Associates, LLC.

8:20 am 9 am (40 mins)

Workshop 2

Unlocked Nucleomonomer Agent (UNA) Oligomer™ System, Challenges and Opportunities

  • Presenter Nancy Fuselli, B.Sc. - Director, Drug Development, Arcturus Therapeutics

9 am 9:40 am (40 mins)

Workshop 2

Unique Analytical Challenges Associated with the CMC Development of mRNA Therapeutics

  • Presenter Kristian Link, Ph.D. - Senior Manager, Analytical Development, Moderna Therapeutics

9:40 am 10:10 am (30 mins)

Workshop 2

Refreshment Break

10:10 am 10:50 am (40 mins)

Workshop 2

Manufacturing Innovation through Partnership

  • Presenter Eduardo Paredes, Ph.D. - Manager, Oligonucleotide Process Development, Nitto Denko Avecia, Inc.

10:50 am 11:30 am (40 mins)

Workshop 2

Practical, Quality and Regulatory Considerations to Manufacture API for Phase 1 Clinical Studies

  • Presenter Kevin Fettes, Ph.D. - Principal and Founder, FTS Pharma Consulting, LLC

11:30 am 12 pm (30 mins)

Workshop 2

Panel Discussion

8 am 8:15 am (15 mins)

Workshop 3

Workshop Moderator's Welcome and Opening Remarks

This workshop will provide a high level primer on the use of CRISPR and genome editing technologies in both research and therapeutic applications. An overview of the discovery, preclinical, clinical, CMC, manufacturing and regulatory considerations for CRISPR and genome editing will be discussed. The current challenges and opportunities of CRISPR and genome editing technologies will also be presented.

Topics to be Discussed:

  • Creative Chemical Modifications and Synthesis Approaches
  • Considerations for Safety, Quality, Regulatory and Off-target Effects
  • Advances in Genome Editing TechnologiesDelivery Strategies
  • What Can Be Learned from Oligonucleotides and mRNA?
  • Applications of CRISPR in Research and Therapeutics
  • Chairman Cecilia Fernández, Ph.D. - Director, Platform Development, Editas Medicine

8:15 am 8:45 am (30 mins)

Workshop 3

CRISPR-based Genome Editing: Considerations for Therapeutic Applications

  • Cecilia Fernández, Ph.D. - Director, Platform Development, Editas Medicine

8:45 am 9:15 am (30 mins)

Workshop 3

Synthetic sgRNA Enables Highly Efficient and Consistent CRISPR Editing of Cells for Therapeutic Applications

Achieving high editing efficiencies in CRISPR therapeutic applications while maintaining consistency remains a significant challenge. Traditional methods for generating guide RNAs yield molecules of inconsistent length and quality that affect genome editing efficiency. We demonstrate that synthetic sgRNA produces consistent editing efficiencies superior to two-piece crRNA:tracrRNA complexes and IVT-derived guides.

  • Kevin Holden, Ph.D. - Head of Synthetic Biology, Synthego

9:15 am 9:45 am (30 mins)

Workshop 3

Tuning the CRISPR Code: Chemically Modified RNAs Enhance CRISPR Genome Editing in Human Primary Cells

Targeted genome editing with engineered nucleases is increasingly allowing researchers to introduce precise sequence modifications at almost any site within the genome with nucleotide resolution. CRISPR/Cas-mediated genome editing relies on guide RNAs to direct site-specific DNA cleavage mediated by the Cas endonuclease. In this study (Hendel et al., Nat. Biotechnol. 33, 985–989 (2015), doi: 10.1038/nbt.3290), we chemically synthesized 100-nucleotide single guide RNAs (sgRNAs) targeting three different genes (IL2RG, HBB, and CCR5), alongside sgRNA variants containing modified nucleotides at both ends selected for their potential to impact the stability and immunostimulatory properties of nucleic acids. We demonstrate that chemically synthesized sgRNAs can facilitate genome editing in human cell lines when co-delivered with Cas9-encoding plasmid. We further show that sgRNAs containing modified nucleotides dramatically enhance genome editing compared to unmodified sgRNAs. When co-delivering chemically modified sgRNAs and Cas9 mRNA we observe >90% in/del frequencies in human cells lines, ~70% in human primary T cells, and ~40% in CD34+ hematopoietic stem and progenitor cells (HSPCs), despite detecting no activity for unmodified sgRNAs in the latter two cell types. We observe no apparent cellular toxicity and analysis of off-target activities indicate that chemically modified sgRNAs typically retain high specificity. Future studies could investigate a larger variety of chemical modifications, explore different locations of the modifications for rational design of optimized sgRNAs, as well as the mechanism for the enhanced activity of modified sgRNAs. In conclusion, we suggest that next-generation chemically modified sgRNAs have the potential to substantially improve a wide array of CRISPR/Cas biotechnological and therapeutic applications.

  • Ayal Hendel - Principal Investigator, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University

9:45 am 10:15 am (30 mins)

Workshop 3

Refreshment Break

10:15 am 10:45 am (30 mins)

Workshop 3

Applying Agilent’s CRISPR/Cas Technology and Services to the Current Market with Emphasis on gRNA Production and Analysis

The first portion of the discussion will include current market trends in both research and development of therapeutics using CRISPR/Cas gene editing technology and briefly touch on Agilent’s solutions for enabling research. The subsequent portion of the discussion will focus on considerations and approaches that Agilent is using for gRNA production and analysis. A case study will be presented including results from process establishment for gRNA production. Come learn how Agilent is helping its customers turn this exciting technology into a therapeutic reality.

  • Joe Guiles, Ph.D. - Head of Development, Nucleic Acid Solutions Division, Agilent Technologies, Inc.
  • Blake Unterreiner - Director, Business Development & Customer Relation Nucleic Acid Solutions Division, Agilent Technologies, Inc.

10:45 am 11:15 am (30 mins)

Workshop 3

Delivering Genome Editing: Strategies from RNA Therapeutics

Speaker TBA

  • Muthiah (Mano) Manoharan, Ph.D. - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.

11:15 am 12 pm (45 mins)

Workshop 3

Panel Discussion

8 am 8:15 am (15 mins)

Workshop 4

Workshop Opening Remarks

Peptides are being developed for a diverse set of clinical uses and have a variety of potencies.  Because processes for manufacture of peptides use common platforms, peptides are often prepared in multi-use (non-dedicated) environments.  Multi- use facilities for non-commercial manufacture present several risk assessment issues that are gaining increasing regulatory scrutiny.  Key topics include dedicated vs multiuse, cleaning validation, occupational containment, facilities design, quality aspects of control strategies.

Topics to be Discussed:

  • OEL Banding
  • Regulatory Requirements for Cleaning Validation
  • Multi-use facilities- Design and Support Considerations
  • Cleaning Validation
  • Risk Assessment and Containment Strategies for Peptide Drug Products
  • Workshop Leader Gary F. Musso, Ph.D. - President, Musso and Associates LLC
  • Workshop Leader Trishul Shah - Associate Director, Business Development, North America, PolyPeptide Laboratories

8:15 am 8:45 am (30 mins)

Workshop 4

Safe Handling of Peptides: From Oligonucleotides to Peptide Hormones - Quality and Worker Safety Requirements in Multi-Purpose Facilities

The safe handling of peptides ranging in toxicity and potency from oligonucleotides to peptide hormones requires appropriate assessment of their toxicity and potency and placing into occupational health categories.  This assessment should be linked to appropriate controls and containment.  As the drug progresses through clinical development, developing quantitative assessments for both worker exposure (Occupational Exposure Limits) and quality assurance (Permitted Daily Exposure for establishing cleaning limits to meet the EMA cross-contamination guideline) are required.  Parallel to these quantitative health-based risk assessments should be development of validated methods for measuring the peptides in air and on surfaces.  This talk will cover scientifically supportable and systematic approaches that can be applied to peptide products in multi-purpose facilities in these critical areas to speed these drugs to market.

  • Presenter Allan Ader, Ph.D. - Managing Director, SafeBridge Consultants Inc.

8:45 am 9:15 am (30 mins)

Workshop 4

Manufacturing Risk Assessment at API CMOs: How to Reduce Cross Contamination in a Multi-Product Environment

  • Presenter Robert Geiger - Vice President, Quality, AmbioPharm

9:15 am 9:45 am (30 mins)

Workshop 4

Risk Assessment Aspects of Working with Peptides for Drug Product in a Multi-Product Environment

  • Presenter Mimoun Ayoub, Ph.D. - Director, Global Peptides, Oligonucleotides, Lipids, Carbohydrates & Injectables Platforms, CordenPharma International, Switzerland

9:45 am 10:15 am (30 mins)

Workshop 4

Refreshment Break

10:15 am 10:50 am (35 mins)

Workshop 4

Aspects of Cleaning of Equipment Used for Multi-Product Manufacturing

e presentation will address important topics when a new Risk and Science based cleaning system is designed. Some of these topics include: 1) How can the risk for cross contamination related to cleaning be decreased? 2) What to do in order to be in compliance with the new EU-GMP directives regarding calculation of carryover levels based on Toxicological evaluations?  3) The importance of the cleaning process (and not just cleaning)

  • Presenter Henric Byhlin - Global Development Manager, Polypeptide Group

10:50 am 11:25 am (35 mins)

Workshop 4

Crisis to Compliance: Reconciling Hazardous Materials in an Operating Facility

Case study of improvements and new construction required to address critical fire department corrections for a growing and operating peptide facility. Emphasis is on real world assessments, calculations, and justifications needed to comply with California Building and Fire Codes; also applicable to IBC jurisdictions. Session will include brief discussion of control areas, H-x occupancies, building separations and other methods to compartmentalize chemical use in compliance with codes.

  • Presenter Steve Tomko, AIA - Architectural Discipline Lead, CRB

12 pm 12:01 pm (1 mins)

Main agenda

Close of Morning Workshops

12 pm 1:30 pm (90 mins)

Workshop 1

Lunch on Your Own

1:30 pm 2:15 pm (45 mins)

Workshop 1

High Throughput Purification Process Development of Synthetic Peptides using a Quality by Design Approach

This presentation briefly describes the ideas and principles we are working with in order to shorten development timelines as well as develop robust manufacturing processes. The scope of this presentation is to highlight some of the important parameters to be considered within the purification process development of active synthetic peptides, including phase system optimization, robustness, life time and design of high quality resins. Furthermore, the importance of process understanding and process knowledge by a structured and systematic experimental work (DoE) will be discussed. The responses from DoE will be used to demonstrate the limits of a purification process and thus support a Quality by Design approach (QbD). Although the CQAs (Critical Quality Attributes) of the product have the most prominent place when designing a process, it is not sufficient to design a process only with the CQAs in mind. The scope of the quality concept has to be expanded to encompass all quality attributes of a process, which are: Critical quality attributes of the product, yield, throughput (e.g. kg/day), costs, robustness (e.g. scalability, reproducibility, lack of deviations, out specification, out of trends, reprocesses etc.).

  • Presenter Per Moller - Purification Scientist, PolyPeptide Group

2:15 pm 2:45 pm (30 mins)

Workshop 1

Expanding the Toolbox of Peptide Purification

The impurities produced in the solid-phase synthesis of peptides are structurally related and typically have similar chromatographic properties, which can lead to difficulties in the preparation of high purity, clinical-grade peptides.  This can be further complicated when the structural features of the peptides themselves leads to degradation during the chromatography process.  This presentation will describe a number of case studies where a judicious choice of media, buffer and isolation technique has been required in order to produce peptides of the appropriate quality.

  • Presenter Steven McIntyre - Senior Team Leader, Almac Group

2:45 pm 3 pm (15 mins)

Workshop 1

Refreshment Break

3 pm 3:30 pm (30 mins)

Workshop 1

Peptide Purification: Bridging the Gap Between Discovery and Development

Production of high purity synthetic peptides can be a challenging effort due to the complexity of the mixtures and a heavy reliance on chromatographic resources.  The “need for speed” in a time of limited resources adds to this challenge.  By coupling the use of internal and external resources, the process can be streamlined while providing learning opportunities along the way.  In this presentation, we report on this strategy which was employed to efficiently move a critical target through the development phase to produce GMP quality material on kilogram scale.

  • Presenter Regina Black - Senior Research Investigator II, Bristol-Myers Squibb

3:30 pm 4 pm (30 mins)

Workshop 1

Downstream Purification Peptide Case Study: The Fuzeon Story

  • Brad DeHoff, Ph.D. - Director, R&D Strategy, Corden Pharma Colorado Inc

4 pm 5 pm (60 mins)

Workshop 1

Panel Discussion

1 pm 1:15 pm (15 mins)

Workshop 5

Welcome and Introduction to Workshop

This workshop will focus on quality expectations for oligonucleotide drug products. A number of new guidances have emerged from the FDA and the EMA recently, and this workshop will explore the application of the underlying quality concerns in those guidances to oligonucleotide drug products. The case studies chosen will span early development through marketed products, in all cases maintaining a focus on the oligonucleotide.

Topics to be Discussed:

  • Emerging Regulatory Expectations Regarding Quality of Drug Products
  • Terminal Sterilization
  • Combination Products
  • Co-formulated Products
  • Complex Drug Products
  • Workshop Leader James McArdle, Ph.D. - President, McArdle & Associates, LLC

1:15 pm 2 pm (45 mins)

Workshop 5

Expectations for Quality in Oligo Drug Products

  • Presenter René Thürmer, Ph.D. - Deputy Head, Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices

2 pm 2:45 pm (45 mins)

Workshop 5

Early Experience with Terminal Sterilization of Oligonucleotides

  • Presenter Gregory Hardee, Ph.D. - Senior Pharmaceutical Consultant, Oligo Development

2:45 pm 3 pm (15 mins)

Workshop 5

Refreshment Break

3 pm 3:45 pm (45 mins)

Workshop 5

Quality Considerations in Developing an Oligo PFS Combination Product

  • Presenter Brent Golec - Assistant Director, Pharmaceutical Development, Ionis Pharmaceuticals

3:45 pm 4:30 pm (45 mins)

Workshop 5

Pharmaceutical Quality/CMC Aspects of Lipid Nanoparticle Formulations of Nucleic Acids

  • Presenter Christopher Barbosa, Ph.D. - Director of Technology Development, Acuitas Therapeutics

4:30 pm 5 pm (30 mins)

Workshop 5

Panel Discussion

1 pm 5 pm (240 mins)

Workshop 6

Welcome and Introductions by Workshop Leader

This workshop will provide a high level primer on the development of messengerRNA (mRNA) therapeutics. An overview of the discovery, preclinical, clinical, CMC, manufacturing and regulatory considerations for mRNA therapeutics will be discussed. The current challenges and opportunities of these complex molecules will also be presented.

Topics to be discussed include:

  • The Anatomy of an mRNA
  • mRNA Chemistries
  • Manufacturing Strategies for mRNA
  • Control Strategies for mRNA
  • Applications of mRNA as Therapeutics and Vaccines
  • Workshop Leader James Thompson, Ph.D. - Head CMC Project Management, Moderna Therapeutics, Inc.

1:15 pm 2 pm (45 mins)

Workshop 6

Introduction to mRNA Therapeutics

  • James Thompson, Ph.D. - Head CMC Project Management, Moderna Therapeutics, Inc.

2 pm 3 pm (60 mins)

Workshop 6

Design and Manufacturing of Chemically Modified mRNA Therapeutics

  • Anton McCaffrey, Ph.D. - Senior Director of Research and Development, Biology, TriLink BioTechnologies, Inc.

3 pm 3:30 pm (30 mins)

Workshop 6

Refreshment Break

3:30 pm 4 pm (30 mins)

Workshop 6

Delivery Strategies for mRNAs

  • Paul Burke, Ph.D. - Principal, Burke Bioventures LLC

4 pm 4:30 pm (30 mins)

Workshop 6

Applications of mRNA Therapeutics

  • Patrick Baumhof, Ph.D. - Vice President Formulation & Delivery, CureVac AG

4:30 pm 5 pm (30 mins)

Workshop 6

Panel Discussion

Speaker TBA

1 pm 1:15 pm (15 mins)

Workshop 7

Workshop Opening Remarks

  • Workshop Leader Laixin Wang, Ph.D. - Vice President of Bioanalytical, NovaBioAssays, LLC

1:15 pm 1:50 pm (35 mins)

Workshop 7

PK/PD Modeling - Antisense Oligonucleotides (ASO) and Current Status

  • Presenter Yanfeng Wang, Ph.D. - Executive Director, PK and Clinical Pharmacology, Ionis Pharmaceuticals

1:50 pm 2:25 pm (35 mins)

Workshop 7

PK/PD Profiling of Therapeutic Oligonucleotides: A Combinatorial Method using Peptide Nucleic Acid Hybridization and Quantigene branched-DNA Assays

  • Presenter Bruno Godinho, Ph.D. - Milton-Safenowitz PostDoctoral Fellow, RNA Therapeutics Institute, University of Massachusetts Medical School

2:25 pm 3 pm (35 mins)

Workshop 7

Applications of Hybridization ELISA Assays in Regulated Bioanalysis of Oligonucleotide Therapeutics

  • Presenter Sarah Greenlee - Senior Scientist, Ionis Pharmaceuticals

3 pm 3:30 pm (30 mins)

Workshop 7

Refreshment Break

3:30 pm 4 pm (30 mins)

Workshop 7

Providing Bioanalytical Support to Advance siRNA Drug Development from Pre-Clinical to Clinical Stages

  • Presenter Kirk Brown, Ph.D. - Principal Scientist, Alnylam Pharmaceuticals Inc

4 pm 4:30 pm (30 mins)

Workshop 7

Quantigene Branched-DNA Assay as a Robust, Selective and Sensitive Bioanalytical Method in Support of mRNA Therapeutics

  • Presenter Nanda Balasubramanian - Development Scientist II, Alexion Pharmaceuticals

4:30 pm 5 pm (30 mins)

Workshop 7

Panel Discussion

1 pm 1:20 pm (20 mins)

Workshop 8

Workshop Leaders’ Remarks

Peptides offer notable advantages as drugs including their high biological activity, high specificity and low toxicity. However, peptides also present challenges in drug development. (1) short half-life because they are quickly broken down by proteolytic enzymes; (2) inadequate drug-like pharmaceutical properties such as solubility and chemical and physical stability (3) the polar, chemical nature of peptides prevent them from getting past physiological barriers or membranes, and (4) need to be parenterally delivered (via injection) because oral administration would lead to their degradation in the digestive tract. This workshop will focus on cutting-edge, novel technologies to optimize peptides as therapeutics. Case studies will illustrate the use of these platform technologies to enhance the pharmaceutic properties of peptides. 

Topics to be Discussed:

  • Stabilizing Peptide Backbone
  • Half-life Extension Technologies
  • Creative Formulation Approaches
  • Strategies to Improve Peptide Delivery
  • Other Approaches to Improve Peptide Properties
  • Chairman Ved Srivastava, Ph.D. - Vice President of Chemistry, Intarcia Therapeutics, Inc.
  • Chairman Bruce Morimoto, Ph.D. - Executive Director, Applied Translational Medicine, Celerion, USA

1:20 pm 1:50 pm (30 mins)

Workshop 8

Peptide Stapling and Half-life Extension

As a drug class, peptides offer exquisite specificity and potency, but also present challenges associated with poor stability and short half-life, manifesting in the need for frequent injections, poor patient compliance, and overall compromised efficacy. This workshop will cover various peptide stapling technologies that were reported to improve the peptide stability, potency as well as cell penetration. Also, a novel peptide engineering strategy that incorporates a serum protein binding motif onto a covalent side-chain staple will be discussed as well as its application to exenatide, GLP1R agonist, to enhance its helicity and as a consequence, its potency and serum half-life.

  • Weijun Shen - Principal Investigator, California Institute for Biomedical Research

2:10 pm 3 pm (50 mins)

Workshop 8

An Insider’s Guide to PEG as a Half-life Extender

  • Chris Holmes, Industry Consultant

3 pm 3:30 pm (30 mins)

Workshop 8

Refreshment Break

3:30 pm 4:20 pm (50 mins)

Workshop 8

Recent Advances in Peroral Delivery of Peptide Drugs

  • Nozer Mehta - Principal, Peptide Technologies LLC

4:20 pm 5 pm (40 mins)

Workshop 8

Half-life Extension Strategies for Peptides as Seen Through the Lens of the GLP-1 Class

  • Christopher Rhodes, Ph.D. - President and CEO, Drug Delivery Experts

5 pm 5:01 pm (1 mins)

Main agenda

Close of Afternoon Workshops